Industry Relationships of Faculty Members
UAMS faculty members may have business or collaborative relationships with other companies in the healthcare industry. These relationships may include activities such as research, education and training, consulting, ownership, or intellectual property interests. While these relationships are beneficial for advancing research and developing new technologies and therapies to benefit patients and improve health outcomes, they may also give rise to potential conflicts of interest.
UAMS has established policies and procedures to assure that private interests of faculty members and their immediate family do not improperly influence medical decision-making. UAMS faculty members are required to disclose industry relationships to the UAMS Conflict of Interest Office at least annually. The Conflict of Interest Committee will then evaluate and monitor these relationships to make sure that faculty relationships with industry are consistent with the UAMS objectives of placing the needs of patient first and conducting research with integrity, objectivity, and an emphasis on the safety of volunteers.
*Industry Relationship Types
Ownership Interest – such as stock options, or other types or ownership interest.
Intellectual Property Interest – such as patents, copyrights, licenses, or royalties.
Fiduciary Relationships – such as service as an officer, executive, board member, or advisor.
Remuneration – such as salary or other compensation for items such as consulting, honoraria, speaking engagements, teaching presentations, authorship, travel reimbursement, etc.
|Month||Year||Investigator||Last Name||Name of Entity||Type of Interest||Value|
|April||2008||W. Brooks Gentry, MD||Gentry||InterveXion Therapeutics, LLC||Ownership||< $5,000|
|April||2008||W. Brooks Gentry, MD||Gentry||InterveXion Therapeutics, LLC||Intellectual Property||< $5,000|
|July||2011||Laura James, MD||James||Acetaminophen Toxicity Diagnostics, LLC||Intellectual Property||< $5,000|
|July||2011||Laura James, MD||James||Acetaminophen Toxicity Diagnostics, LLC||Ownership||< $5,000|
|May||2011||William Culp, MD||Culp||Cerevast Therapeutics, Inc.||Intellectual Property||< $5,000|
|May||2011||Richard Nicholas, MD||Nicholas||Musculoskeletal Transplant Foundation||Fiduciary Relationship||$5,000 – $25,000|
|May||2011||Stavros Manolagas, MD , PhD||Manolagas||Radius Health, Inc.||Ownership||> $100,000|
|Dec||2011||Smith, Charles W||Smith||eDocAmerica.com, LLC||Ownership||> $100,000|
|July||2012||Eren Erdem||Erdem||Dfine, Inc.||Ownership||< $5,000|
|July||2012||Eren Erdem||Erdem||Dfine, Inc.||Compensation||$25,000 – $50,000|
|Dec||2012||Bart Balogie||Barlogie||Signal Genetics||Intellectual Property||< $5,000|
|Feb||2013||T. Glenn Pait||Pait||DePui Spine||Intellectual Property||$5,000-$25,000|
|April||2013||Curtis Lowery||Lowery||AirToco, LLC (ADD NEW)||Ownership||<$5,000|